logo
No sit-ups or crunches — use this 10-minute standing ab workout instead to sculpt a stronger core

No sit-ups or crunches — use this 10-minute standing ab workout instead to sculpt a stronger core

Tom's Guide09-05-2025

Building a stronger and more defined core is all fun and games until you tire of getting down on one of the best yoga mats and churning out rep after rep of sit-ups and crunches.
Floor ab workouts (for some) can feel repetitive and strain the neck and lower back. Even with a mat, they're not always the most comfortable option. So, here's a no-repeats 10-minute all-standing core workout to add to your repertoire.
This one comes from one of my all-time favorite trainers, Maddie Lymburner, better known as MadFit on YouTube, where she shares accessible, easy-to-follow routines.
I worked my way through plenty of her ab workouts during the COVID lockdown because they were quick to tag onto the end of a run or a longer workout, and they never relied on obscure moves or required any equipment.
The workout I'm sharing ticks all the boxes. It takes just ten minutes, can be done almost anywhere as long as you can watch the video, involves no repeats (you won't get bored) and, best of all, it's all standing with no floor work required.
Let's take a look...
This standing core workout might skip the mat, but it doesn't skip the burn. You'll spend the full 10 minutes on your feet and engage your core through a range of movements.
Get instant access to breaking news, the hottest reviews, great deals and helpful tips.
Expect a lot of controlled twisting, bending at the knees and lifting through the hips, all of which fire up your core muscles without lying down.
Standing core workouts are a great option if you're looking to work your abs without the neck cricks and tailbone discomfort that often come with floor-based moves.
Standing exercises feel more natural, often mimic ways we move in daily life and fire up not just the abs but also the legs, glutes and even some of the upper body.
That makes them sneakily effective and ideal for building functional strength you'll actually use, whether you're picking up shopping bags or twisting to reach something in the backseat.
They also tend to be easier on the joints and kinder to the lower back, which is great if you've ever finished a crunch session feeling it more in your spine than your core.
And because standing moves often involve twists, bends and working across different planes of motion, they can also improve mobility, balance and posture, all while delivering that satisfying core burn.
So yes, even without hitting the mat, your abs will still get the message loud and clear. Not convinced after trying one round of MadFit's 10-minute routine? Try throwing in an extra round or two!

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

COR Q1 Earnings Call: Specialty Expansion, RCA Impact, and International Softness Highlight Results
COR Q1 Earnings Call: Specialty Expansion, RCA Impact, and International Softness Highlight Results

Yahoo

timean hour ago

  • Yahoo

COR Q1 Earnings Call: Specialty Expansion, RCA Impact, and International Softness Highlight Results

Healthcare distributor Cencora (NYSE:COR) met Wall Street's revenue expectations in Q1 CY2025, with sales up 10.3% year on year to $75.45 billion. Its non-GAAP profit of $4.42 per share was 7.9% above analysts' consensus estimates. Is now the time to buy COR? Find out in our full research report (it's free). Revenue: $75.45 billion vs analyst estimates of $75.7 billion (10.3% year-on-year growth, in line) Adjusted EPS: $4.42 vs analyst estimates of $4.10 (7.9% beat) Adjusted EBITDA: $1.32 billion vs analyst estimates of $1.22 billion (1.7% margin, 7.6% beat) Operating Margin: 1.4%, in line with the same quarter last year Market Capitalization: $55.09 billion Cencora's first quarter results were shaped by broad-based strength in its U.S. Healthcare Solutions segment, with management attributing growth to rising demand for specialty medications and higher utilization across health systems and specialty physician practices. CEO Bob Mauch highlighted the company's investments in end-to-end pharmaceutical services and deepening partnerships with providers as pivotal to this performance. The recent integration of Retina Consultants of America (RCA) was cited as a key contributor to gross profit margin expansion, with CFO Jim Cleary noting, 'RCA does add meaningfully to gross profit margin and operating margin… it is a higher-margin business than our core distribution business.' Management also pointed to ongoing productivity initiatives and a smaller-than-expected COVID-19 headwind as supporting factors. Looking ahead, Cencora's outlook is informed by its positioning in specialty pharmaceuticals, expectations for continued growth in the U.S. market, and ongoing integration of recent acquisitions. Management anticipates slower revenue growth in the second half of the year, citing tougher comparisons for GLP-1 products and biosimilar competition in mail-order channels. CFO Jim Cleary explained, 'We anticipate our growth will be at the bottom end of the respective ranges,' reflecting these headwinds but also suggesting potential margin benefits from product mix shifts. The company remains focused on expanding value-added services, strengthening specialty offerings across sites of care, and leveraging its data-driven insights to support both biopharma partners and healthcare providers. Management cited several operational and strategic developments as primary drivers of both quarterly results and the company's evolving competitive positioning. Specialty segment momentum: The company's specialty business, including physician practices and health systems, drove broad-based growth, supported by continued investments in services and wraparound offerings such as group purchasing organizations (GPOs) and management service organizations (MSOs). RCA integration impact: The acquisition of Retina Consultants of America contributed to margin expansion due to its higher profitability profile compared to Cencora's core distribution operations. The accounting treatment of RCA's minority interest also resulted in a higher-than-expected EPS contribution. GLP-1 product dynamics: GLP-1 (glucagon-like peptide-1) medications remained a significant revenue driver, though management noted a sequential decline from the prior quarter and minimal profit contribution. The company expects GLP-1 growth rates to moderate in upcoming quarters. International market softness: The International Healthcare Solutions segment experienced subdued demand, particularly in global specialty logistics and consulting related to clinical trials. Management described this as a market-wide issue and adjusted guidance downward to reflect slow recovery in these areas. Broad-based provider growth: Cencora reported growth across its specialty provider verticals, including oncology and retina, with management emphasizing robust positioning across community practices and health systems rather than concentration in any single sub-segment. Cencora's forward outlook is shaped by shifting specialty drug dynamics, international market uncertainty, and continued strategic investments in higher-margin services. Specialty and biosimilar expansion: Management expects specialty pharmaceuticals and biosimilars to remain key growth drivers, with continued investment in value-added services for both biopharma manufacturers and provider partners. The company's MSO and GPO offerings are designed to deepen relationships and capture a greater share of specialty market growth. International segment headwinds: The company anticipates ongoing weakness in its International Healthcare Solutions segment due to soft clinical trial activity and slower-than-expected recovery in global specialty logistics. Management revised down operating income expectations for this segment, citing industry-wide delays in clinical trial starts and subdued demand for consulting services. Product mix and margin effects: Shifts toward higher-margin specialty products and reduced contribution from lower-margin high-priced mail-order products are expected to benefit consolidated operating margins, partially offsetting slower top-line growth. Management noted that these mix effects will likely drive operating income growth above revenue growth, especially in the U.S. segment. Looking forward, the StockStory team will monitor (1) U.S. specialty drug utilization trends and the pace of biosimilar adoption, (2) the trajectory of international clinical trial activity and any signs of a rebound in specialty logistics, and (3) further integration milestones for RCA and the expansion of high-margin MSO services. The evolution of tariff policy and its potential effects on pharmaceutical supply chains will also be an important area for scrutiny. Cencora currently trades at a forward P/E ratio of 17.6×. At this valuation, is it a buy or sell post earnings? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025
Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025

Miami Herald

timean hour ago

  • Miami Herald

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025

CAMBRIDGE, MA / ACCESS Newswire / June 11, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor event: Barclays Speaking the Science Call Series, on Monday, June 16th at 10:00am ET A live webcast of this presentation will be available under "Events and Presentations" in the Investors section of the Moderna website. A replay of this webcast will be archived on Moderna's website for at least 30 days following the presentation. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Investors:Lavina TalukdarSenior Vice President & Head of Investor SOURCE: Moderna, Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store